The abstract is read at the publisher; the summary is JClub's.
mRNA medicine has matured into a clinically validated platform for transient protein expression, with SARS-CoV-2 vaccines demonstrating population-scale proof of readiness.
- Why it matters: The field needs a unified framework to explain why mRNA performance varies, and how transcript design and delivery formulation jointly determine efficacy across preventive and therapeutic uses.
- What they did: This review synthesizes molecular and translational principles, focusing on transcript engineering (cap, UTRs, coding optimization, nucleoside chemistry, poly(A)) and formulation controls (encapsulation, tropism, cytosolic release, stability, route-dependent biodistribution).
- The result: It links platform logic to applications beyond vaccination—protein replacement, lung-directed complementation, regenerative signaling, in vivo antibody production, tumor immunomodulation, genome editing, and transient ex vivo engineering—while highlighting constraints like endosomal escape, immune responses on repeat dosing, and scalable manufacturing.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.